Cart is empty Research and development (R&D) costs for targeted oncology drugs are markedly lower if guided by a companion diagnostic strategy, but current biopharmaceutical business models suggest these savings will not be reflected in more affordable pricing.
Research and development (R&D) costs for targeted oncology drugs are markedly lower if guided by a companion diagnostic strategy, but current biopharmaceutical business models suggest these savings will not be reflected in more affordable pricing.
Leave A Comment